Trouble at the CDC?

Anonymous letters to The Lancet point to problems with the CDC's Center for Global Health, but the agency denies the allegations.

Mar 12, 2012
Bob Grant


Three anonymous letters detailing alleged problems at a global health division run by the US Centers for Disease Control and Prevention provoked a rebuttal from CDC officials.

Allegations in the letters, excerpts of which were published in The Lancet within the last month and aimed at the CDC's 18-month-old Center for Global Health, range from general low morale amongst staffers at the center to misappropriation of funds and clashing with the US Agency for International Development programs. One of the three letters calls for an "objective evaluation" of the global health division, and the other two propose that a Congressional investigation be initiated.

The Lancet editor, Richard Horton, is defending the journal's publication of the letters, saying they are exhortations from CDC staffers whose concerns were stifled by the agency. The letters, he wrote in one of the pieces that excerpts them, "raise questions about leadership, management of resources, proper use of the CDC's authority and power, and the scientific rigor of CDC research."

CDC Director Thomas Frieden and Center for Global Health Director Kevin De Cock, responded in a letter published in The Lancet last week, stating that the allegations of waste and especially suppression of opposing viewpoints are absurd. "We're committed as a scientific agency to open debate," De Cock told ScienceInsider. "I'm committed to that."

De Cock conceded that his center could use some improvement. "We don't claim to be a perfect organization," he told ScienceInsider. But he and Frieden point out in their letter that the program has made strides in helping developing countries fight health emergencies and in training field epidemiologists.

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb


Sponsored Product Updates

Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announced the extension of its CRISPR Screening Service to includeex vivoT lymphocytes. The service extension meets the requirements of immunology-based research in drug discovery,enabling new gene targets to be identified in biologically and potentially therapeutically relevant settings.
pIC50: The Advantages of Thinking Logarithmically
pIC50: The Advantages of Thinking Logarithmically
Watch this webinar from Collaborative Drug Discovery to learn about how using pIC50 helps you get a better sense of the relative potencies, calculate the correct mean of multiple values, and select better sampling doses.
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.